Global Health

R&D strategy:R&D of stratified medicines, serial medicines and progressive medicines according to R&D strategic planning with biologics as the core.

Short-term:For short-term strategies, Kexing Biopharm concentrates on the deep development of new dosage forms, new indications, and long lifecycles of recombinant protein drugs to achieve synergistic effects with the marketed products and strengthen the competitiveness of marketed products.

Medium- and Long-term Strategies:For medium and long-term strategies, Kexing Biopharm concentrates on new antibodies, new proteins, against oncology, immunological diseases, and degenerative diseases, etc. to continuously improve its innovation and advancement capacities in R&D product pipelines.

Global R&D layout:

Shandong R&D Center(Industrial transformation, Product technology improvement)，Shenzhen Medical Research Institute，Research and development of new recombinant protein drugs， Development of all products，Guangzhou R&D Center，Animal vaccine development.

Three major biotechnology systems:Prokaryotic cell technology   Eukaryotic cell technology  Viable bacteria technology

Five technology platforms:KX-FUSION Recombinant protein therapeutics technology platform\KX-BODY Antibody technology platform\K'Exosome delivery technology platform\Probiotic agent R&D and industrialization platform\Vector vaccine technology platform.